Market Cap 39.28B
Revenue (ttm) 6.51B
Net Income (ttm) 1.29B
EPS (ttm) N/A
PE Ratio 25.98
Forward PE 25.40
Profit Margin 19.80%
Debt to Equity Ratio 0.53
Volume 1,698,800
Avg Vol 1,675,582
Day's Range N/A - N/A
Shares Out 283.50M
Stochastic %K 89%
Beta 1.26
Analysts Sell
Price Target $141.62

Company Profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems;...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 800 227 9770
Fax: 866 497 1134
Address:
5301 Stevens Creek Boulevard, Santa Clara, United States
topstockalerts
topstockalerts Oct. 8 at 7:04 PM
UBS upgraded Agilent Technologies Inc. from Neutral to Buy, saying the life-sciences tools maker is positioned for above-peer growth driven by new product launches, improving demand in China, and strength in its specialty manufacturing business. The broker raised its price target to $170 from $130, implying over 20% upside, and said investors are underestimating the durability of Agilent’s growth compared with peers. UBS expects Agilent’s sales growth to accelerate to over 6% by fiscal 2027, giving it a four-year CAGR of about 6%, versus 4.5% for peers. “As these proof points become clear, we expect the stock to re-rate higher,” analysts wrote. Recent instrument launches, including the Null III liquid chromatography system and Pro iQ mass spectrometer, should help Agilent capture pent-up demand from pharmaceutical QA/QC labs. Improved biotech funding and stimulus measures are also boosting demand for analytical instruments in China, which accounts for about 20% of Agilent’s sales. $A
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 8 at 5:45 PM
0 · Reply
stockstelegraph
stockstelegraph Oct. 8 at 2:39 PM
🚀 Analyst Upgrades (Oct 8, 2025): $CEG ↑ Seaport Global → Buy (PT $407) $FCX ↑ Citigroup → Buy (PT $48) $A ↑ UBS → Buy ($130$170) $ARCB ↑ Citigroup → Buy ($79$89) $AXS ↑ Wells Fargo → Overweight ($105$123) #StockUpgrades #WallStreet #AnalystRatings #StocksToWatch #InvestSmart #MarketNews #TradingIdeas
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 9:44 AM
Rothschild & Co updates rating for Agilent Technologies ( $A ) to Buy, target set at 165.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 8 at 7:40 AM
Enter: $A NOV 21 2025 $140 CALLS Buy in Price: $6.70 - $7.60 Take Profit: $17.94 Stop Bleeding: $6.69 ROI Potential: 136% Exit Within: 277 Minutes https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 7 at 6:16 PM
$A Share Price: $138.75 Contract Selected: Jan 16, 2026 $140 Calls Buy Zone: $7.99 – $9.87 Target Zone: $13.83 – $16.91 Potential Upside: 64% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Oct. 7 at 4:06 PM
Evercore ISI Group has adjusted their stance on Agilent Technologies ( $A ), setting the rating to In-Line with a target price of 128 → 140.
0 · Reply
Estimize
Estimize Oct. 7 at 2:48 PM
Wall St is expecting 1.58 EPS for $A Q4 [Reporting 12/01 AMC] http://www.estimize.com/intro/a?chart=historical&metric_name=eps&utm_content=
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 7 at 12:07 PM
$A 1 2 3 4 OCT 25 🔥
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 7 at 4:09 AM
Enter: $A NOV 21 2025 $145 CALLS Buy in Price: $5.00 - $5.90 Take Profit: $12.80 Stop Bleeding: $5.19 ROI Potential: 117% Exit Within: 175 Minutes https://moneygroup.us/alerts
0 · Reply
Latest News on A
Agilent Announces Cash Dividend of 24.8 Cents per Share

Sep 17, 2025, 4:05 PM EDT - 21 days ago

Agilent Announces Cash Dividend of 24.8 Cents per Share


Agilent Technologies, Inc. (A) Q3 2025 Earnings Call Transcript

Aug 27, 2025, 8:00 PM EDT - 6 weeks ago

Agilent Technologies, Inc. (A) Q3 2025 Earnings Call Transcript


Life sciences firm Agilent raises annual revenue outlook

Aug 27, 2025, 4:03 PM EDT - 6 weeks ago

Life sciences firm Agilent raises annual revenue outlook


Agilent Announces CFO Transition

Jul 15, 2025, 8:30 AM EDT - 3 months ago

Agilent Announces CFO Transition


Agilent to Showcase New Products and Innovations at HPLC 2025

Jun 12, 2025, 8:00 AM EDT - 4 months ago

Agilent to Showcase New Products and Innovations at HPLC 2025


Agilent Names August Specht as Chief Technology Officer

May 28, 2025, 8:30 AM EDT - 4 months ago

Agilent Names August Specht as Chief Technology Officer


Agilent to Participate in Jefferies Global Healthcare Conference

May 15, 2025, 4:14 PM EDT - 5 months ago

Agilent to Participate in Jefferies Global Healthcare Conference


Scale Has Its Advantages: 3 A-Rated REIT Monopolies

May 10, 2025, 7:00 AM EDT - 5 months ago

Scale Has Its Advantages: 3 A-Rated REIT Monopolies

AMT DLR EXR MAA O PLD PSA


Agilent to Participate in TD Cowen Health Care Conference

Feb 27, 2025, 9:29 PM EST - 7 months ago

Agilent to Participate in TD Cowen Health Care Conference


Agilent Technologies, Inc. (A) Q1 2025 Earnings Call Transcript

Feb 26, 2025, 9:28 PM EST - 7 months ago

Agilent Technologies, Inc. (A) Q1 2025 Earnings Call Transcript


topstockalerts
topstockalerts Oct. 8 at 7:04 PM
UBS upgraded Agilent Technologies Inc. from Neutral to Buy, saying the life-sciences tools maker is positioned for above-peer growth driven by new product launches, improving demand in China, and strength in its specialty manufacturing business. The broker raised its price target to $170 from $130, implying over 20% upside, and said investors are underestimating the durability of Agilent’s growth compared with peers. UBS expects Agilent’s sales growth to accelerate to over 6% by fiscal 2027, giving it a four-year CAGR of about 6%, versus 4.5% for peers. “As these proof points become clear, we expect the stock to re-rate higher,” analysts wrote. Recent instrument launches, including the Null III liquid chromatography system and Pro iQ mass spectrometer, should help Agilent capture pent-up demand from pharmaceutical QA/QC labs. Improved biotech funding and stimulus measures are also boosting demand for analytical instruments in China, which accounts for about 20% of Agilent’s sales. $A
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 8 at 5:45 PM
0 · Reply
stockstelegraph
stockstelegraph Oct. 8 at 2:39 PM
🚀 Analyst Upgrades (Oct 8, 2025): $CEG ↑ Seaport Global → Buy (PT $407) $FCX ↑ Citigroup → Buy (PT $48) $A ↑ UBS → Buy ($130$170) $ARCB ↑ Citigroup → Buy ($79$89) $AXS ↑ Wells Fargo → Overweight ($105$123) #StockUpgrades #WallStreet #AnalystRatings #StocksToWatch #InvestSmart #MarketNews #TradingIdeas
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 9:44 AM
Rothschild & Co updates rating for Agilent Technologies ( $A ) to Buy, target set at 165.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 8 at 7:40 AM
Enter: $A NOV 21 2025 $140 CALLS Buy in Price: $6.70 - $7.60 Take Profit: $17.94 Stop Bleeding: $6.69 ROI Potential: 136% Exit Within: 277 Minutes https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 7 at 6:16 PM
$A Share Price: $138.75 Contract Selected: Jan 16, 2026 $140 Calls Buy Zone: $7.99 – $9.87 Target Zone: $13.83 – $16.91 Potential Upside: 64% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Oct. 7 at 4:06 PM
Evercore ISI Group has adjusted their stance on Agilent Technologies ( $A ), setting the rating to In-Line with a target price of 128 → 140.
0 · Reply
Estimize
Estimize Oct. 7 at 2:48 PM
Wall St is expecting 1.58 EPS for $A Q4 [Reporting 12/01 AMC] http://www.estimize.com/intro/a?chart=historical&metric_name=eps&utm_content=
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 7 at 12:07 PM
$A 1 2 3 4 OCT 25 🔥
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 7 at 4:09 AM
Enter: $A NOV 21 2025 $145 CALLS Buy in Price: $5.00 - $5.90 Take Profit: $12.80 Stop Bleeding: $5.19 ROI Potential: 117% Exit Within: 175 Minutes https://moneygroup.us/alerts
0 · Reply
DylanGFM
DylanGFM Oct. 6 at 8:36 PM
$A nice move it put in. Somebodies happy😏 This stock has such an OG ticker symbol that it reminds you of itself when you typo enter the letter "A" into your buy window😂
0 · Reply
Mrstock2255
Mrstock2255 Oct. 6 at 5:09 PM
$A this list is brutally accurate crazy
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 5 at 2:07 PM
Enter: $A NOV 21 2025 $145 CALLS Buy in Price: $5.90 - $6.00 Take Profit: $8.32 Stop Bleeding: $5.19 ROI Potential: 41% Exit Within: 260 Minutes https://moneygroup.us/alerts
0 · Reply
patten1962
patten1962 Oct. 4 at 11:32 AM
$PACB ●In 2028 $ILMN offered $1.2B to buy PacBio. ●That would be $8.00 per share according to Ai. ●Today the Company is in much better shape. ●PacBio is very undervalued! ●$TMO & $A are the logical companies for M&A. ●Institutional Ownership includes Ark, Softbank, Blackrock, Vanguard.
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:55 PM
$A $RIO $RLYB $EBAY Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 11:01 AM
$A: Unusual Options Activity Alerted CALL flow observed 200x contracts at Strike price of $110 Exp on 01/15/2027 with Premium of $812K and showing BULLISH Sentiment
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 3 at 5:05 AM
Enter: $A NOV 21 2025 $140 CALLS Buy in Price: $6.20 - $6.50 Take Profit: $11.16 Stop Bleeding: $5.46 ROI Potential: 80% Exit Within: 345 Minutes https://moneygroup.us/alerts
0 · Reply
whiteboytrippin
whiteboytrippin Oct. 2 at 2:21 PM
$A It is not clear to me why I went bearish on this. :-|. I am getting my ass handed to me.
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:04 PM
Barclays has updated their rating for Agilent Technologies ( $A ) to Equal-Weight with a price target of 150.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 2 at 11:08 AM
Enter: $A NOV 21 2025 $140 CALLS Buy in Price: $6.17 - $7.20 Take Profit: $11.48 Stop Bleeding: $5.43 ROI Potential: 86% Exit Within: 315 Minutes https://moneygroup.us/alerts
0 · Reply
patten1962
patten1962 Oct. 2 at 11:07 AM
$PACB From Ai. The Value of PacBio is a Minimum of $1.2B Maybe $TMO or $A will pay $1.5B? Of course I am guessing but has to be a reason so many Institutions own this!
0 · Reply
TheClockworkGroup
TheClockworkGroup Oct. 1 at 9:45 PM
$A #NYSE | The markets are unpredictable, but with #WaveE, one of our cutting-edge #AI-driven #algorithmic #breakout #daytrading strategies, you too can make calculated trades like a pro! Scalped profits of $4,369.12 trading #AgilentTechnologiesInc., $A shares today! Experience 100% automation and compatibility with @MultiCharts, @NinjaTrader, @TradeStation & @TradingView...
0 · Reply